OncoTherapy Science, Tokushukai to Set up Joint Venture Company for Clinical Trial and Research Support.Tokyo, Japan, May 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - OncoTherapy Science (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). ) announced on May 29 that it has agreed with Tokushukai to establish joint venture company Future Medical Care Research Center in mid-June. To be capitalized Capitalized Recorded in asset accounts and then depreciated or amortized, as is appropriate for expenditures for items with useful lives longer than one year. at 100 million yen ($900,000), the new company will provide support for clinical trials and research activities. In particular, the new company will focus on genomic genomic pertaining to a genome. genomic clone see clone. genomic DNA the DNA sequences making up the genome of an individual. genomic library see gene bank. drug development and advanced medical treatment in the cancer field. Tokushukai & Pise, a Tokushukai group company, and OTC will own 70% and 30%, respectively, of the new company. Going forward, the new company will promote trials and R&D activities at Tokushukai-affiliated hospitals and medical institutions. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion